Abstract 4P
Background
Complications of immediate breast reconstruction caused by chemotherapy or radiotherapy have been debated, but these complications may delay the end of adjuvant treatment and subsequently increase the recurrence. The purpose of this study was to identify risk factors of tissue expander or implant removal and difference of duration from mastectomy to tissue expander or implant removal.
Methods
We conducted a retrospective study of total 11362 breast cancer patients between 2012 and 2017 who were identified in Samsung Medical Center. Eligible patients were total 1091 female breast cancer patients after nipple sparing mastectomy or skin sparing mastectomy with tissue expander or direct implant insertion.
Results
602 (55.2%) patients (group A) have not chemotherapy (CTx), 61 (5.6%) patients (group B) have neoadjuvant CTx and 428 (39.2%) patients (group C) have adjuvant CTx. 897 (82.2%) patients (group D) have not radiotherapy (RTx), 194 (17.8%) patients (group E) have RTx. 1050 (96.2%) patients (group N) have not tissue expander or implant removal and 41 (3.8%) patients (group R) have tissue expander or implant removal. Baseline and pathologic characteristics of patients were not different except N stage between group N and group R. Univariate analysis showed increased pathologic N stage was significantly associated tissue expander or implant removal. (HR = 14.769, 95% CI = 4.338 to 50.284). Tissue expander or implant removal occurred more group B (6.6%) than group A (2.0%) (HR = 3.450, 95% CI = 1.078 to 11.048), more group C (5.8%) than group A (HR = 3.050, 95% CI = 1.515 to 6.141) and more group E (8.8%) than group D (2.7%) (HR = 3.494, 95% CI = 1.839 to 6.639). In multivariate analysis, N stage decreases, tissue expander or implant removal occurred earlier (P < .05). Median time of duration from operation to tissue expander or implant removal was 495 days (range 10-2423 days).
Conclusions
Immediate reconstruction with tissue expander or implant after mastectomy may be a choice of treatment option even in breast cancer patients who will be received chemotherapy or radiotherapy. These results will aid preoperative counselling to patients who are concerned about complication of immediate reconstruction caused by chemotherapy or radiotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
412P - The evaluation of chromosomal changes in patients with osteosarcoma
Presenter: Nargiza Karimova
Session: Poster display session
Resources:
Abstract
413P - The state of molecular biological markers in osteosarcoma
Presenter: Djamilya Polatova
Session: Poster display session
Resources:
Abstract
414P - Clinical profile of gastrointestinal stromal tumour in Yangon General Hospital
Presenter: Khin Mu
Session: Poster display session
Resources:
Abstract
415P - Adult soft tissue myoepithelial carcinoma: Treatment outcomes and efficacy of chemotherapy
Presenter: Florence Chamberlain
Session: Poster display session
Resources:
Abstract
417P - Clinicopathological profile and survival outcomes of sarcomas from a regional cancer centre in South India
Presenter: Divya Bharathi
Session: Poster display session
Resources:
Abstract
418P - Lessons learnt from treatment of foot sarcomas: Analysis from dedicated sarcoma clinic in North India
Presenter: Satyajit Pawar
Session: Poster display session
Resources:
Abstract
423P - Effectiveness of first-generation 5HT3 receptor antagonist plus dexamethasone plus aprepitant in controlling delayed chemotherapy-induced nausea and vomiting in patients with colorectal cancer: A propensity score-matched analysis
Presenter: Toshinobu Hayashi
Session: Poster display session
Resources:
Abstract
424P - Cancer worry, genetic knowledge, and attitudes towards NGS multigene panel testing among Korean breast cancer patients
Presenter: Ji Soo Park
Session: Poster display session
Resources:
Abstract
425P - Economic and safety evaluation of 5-HT3 recepter antagonist conversion from palonosetron to granisetron in highly and moderately emetogenic chemotherapy: A prospective study
Presenter: Keisuke Yamakita
Session: Poster display session
Resources:
Abstract
426P - Impaired quality of life of caregivers of patients with gastrointestinal cancer undergoing palliative chemotherapy
Presenter: Nobumichi Takeuchi
Session: Poster display session
Resources:
Abstract